Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

Myriad Genetics (NASDAQ: MYGN) will release its first quarter 2026 financial results after market close on May 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day.

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will release its first quarter 2026 financial results after market close on May 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day. Investors can join via live webcast on investor.myriad.com or by telephone after registration; an archived webcast will be available following the call.

Argus Apr 29 session

-3.31% close to close Open Argus

Details

News Market Reaction – MYGN

On Apr 29, the first trading day after this news, MYGN closed 3.31% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Market Context

This announcement simply sets the timing for Myriad Genetics’ Q1 2026 earnings release and conferenc...

Analysis

This announcement simply sets the timing for Myriad Genetics’ Q1 2026 earnings release and conference call, continuing the company’s practice of after-market reporting with a 4:30 pm ET call. Recent history includes FDA approval for MyChoice CDx, new product launches like Precise MRD, and 2025 results showing $824.5 million in revenue and a GAAP net loss of $365.9 million. Investors may focus on how upcoming results update revenue growth, profitability metrics and execution on the “New Myriad” strategy.

Key Figures

Earnings call time: 4:30 pm ET Earnings date: May 5, 2026 2025 revenue: $824.5 million +5 more

Earnings call time

4:30 pm ET

Q1 2026 earnings conference call on May 5, 2026

Earnings date

May 5, 2026

Q1 2026 financial results release after market close

2025 revenue

$824.5 million

Full year 2025, 2% decline from 2024

2025 GAAP net loss

$365.9 million

Full year 2025 results

2025 adjusted EBITDA

$38.9 million

Full year 2025 performance metric

2025 adjusted EPS

$0.06

Full year 2025, as reported in proxy statement

Growth investment

$35 million

Planned redirection into commercial and key R&D programs

Shelf registration size

$200,000,000

S-3 shelf prospectus dated February 24, 2026

Previous Earnings date Reports

1 past event · Latest: Feb 16

Same Type 1 event

1. Feb 16

   Earnings date notice

   24h Move

   +0.2%

   Announced Q4 and full year 2025 earnings release and call timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first quarter of 2026.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Myriad Genetics (MYGN) release Q1 2026 earnings and hold the earnings call?

Myriad will release Q1 2026 results after market close on May 5, 2026, with a conference call at 4:30 p.m. ET. According to the company, the call will include a financial overview and business update and will be webcast on investor.myriad.com.

How can investors access the Myriad Genetics (MYGN) May 5, 2026 earnings webcast?

Investors can access the live webcast on investor.myriad.com at the scheduled time. According to the company, an archived webcast will be posted on the same website following the conference call for later review.

Can shareholders join the Myriad Genetics (MYGN) earnings call by telephone and how do they register?

Shareholders can join by telephone by registering in advance to receive a dial-in number and unique PIN. According to the company, registration details are provided on the investor relations site to enable phone participation.

What will Myriad Genetics (MYGN) management cover during the May 5, 2026 earnings call?

Management will provide a financial overview and business update for Q1 2026 during the call. According to the company, the discussion will review quarterly performance and related business developments for the period.

Will Myriad Genetics (MYGN) make an archived replay of the Q1 2026 earnings call available?

Yes, an archived webcast of the call will be available after the live event on investor.myriad.com. According to the company, the archived webcast will remain accessible on the investor relations website following the conference call.